MX2020002015A - Sales de un compuesto y sus formas cristalinas. - Google Patents
Sales de un compuesto y sus formas cristalinas.Info
- Publication number
- MX2020002015A MX2020002015A MX2020002015A MX2020002015A MX2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A MX 2020002015 A MX2020002015 A MX 2020002015A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- compound
- salts
- same
- pyrazin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YVOLUPPVPQLTHT-UHFFFAOYSA-N pyrido[3,4-b]pyrazin-5-amine Chemical compound C1=CN=C2C(N)=NC=CC2=N1 YVOLUPPVPQLTHT-UHFFFAOYSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención pertenece al campo farmacéutico y proporciona las sales farmacéuticamente aceptables del compuesto (S)-7-(4-(1-(metil sulfonil)piperidin-4-il)fenil)-N-(morfolin-2-il metil)pirido[3,4-b]pirazin-5-amina y las formas cristalinas de los mismos, los solvatos y las formas cristalinas de los mismos, las composiciones farmacéuticas que comprenden los mismos, así como los métodos de preparación de los mismos y el uso de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710723169.3A CN109422741A (zh) | 2017-08-22 | 2017-08-22 | 化合物的盐及其晶型 |
| PCT/CN2018/101699 WO2019037737A1 (en) | 2017-08-22 | 2018-08-22 | CRYSTALLINE SALTS AND FORMS OF A COMPOUND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002015A true MX2020002015A (es) | 2020-07-20 |
Family
ID=65439343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002015A MX2020002015A (es) | 2017-08-22 | 2018-08-22 | Sales de un compuesto y sus formas cristalinas. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11396507B2 (es) |
| EP (1) | EP3672972A4 (es) |
| JP (1) | JP7162964B2 (es) |
| KR (1) | KR102650181B1 (es) |
| CN (4) | CN109422741A (es) |
| AU (1) | AU2018320010B2 (es) |
| CA (1) | CA3072525A1 (es) |
| CL (1) | CL2020000439A1 (es) |
| EA (1) | EA202090532A1 (es) |
| IL (1) | IL272835A (es) |
| MX (1) | MX2020002015A (es) |
| MY (1) | MY200551A (es) |
| PE (1) | PE20200887A1 (es) |
| PH (1) | PH12020500366A1 (es) |
| SG (1) | SG11202001301RA (es) |
| TW (1) | TWI816690B (es) |
| UA (1) | UA125942C2 (es) |
| WO (1) | WO2019037737A1 (es) |
| ZA (1) | ZA202001029B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114835682B (zh) * | 2022-06-17 | 2024-04-26 | 华东理工常熟研究院有限公司 | 一种吡虫啉的盐及其制备方法与用途 |
| WO2025140517A1 (zh) * | 2023-12-28 | 2025-07-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| CN105732596B (zh) * | 2012-11-19 | 2019-05-28 | 齐鲁制药有限公司 | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 |
-
2017
- 2017-08-22 CN CN201710723169.3A patent/CN109422741A/zh active Pending
-
2018
- 2018-08-22 UA UAA202001775A patent/UA125942C2/uk unknown
- 2018-08-22 CN CN202111609042.1A patent/CN114369093B/zh active Active
- 2018-08-22 EA EA202090532A patent/EA202090532A1/ru unknown
- 2018-08-22 KR KR1020207007272A patent/KR102650181B1/ko active Active
- 2018-08-22 CN CN202111634327.0A patent/CN114044776B/zh active Active
- 2018-08-22 US US16/641,054 patent/US11396507B2/en active Active
- 2018-08-22 MX MX2020002015A patent/MX2020002015A/es unknown
- 2018-08-22 CN CN201880052524.1A patent/CN111094284A/zh active Pending
- 2018-08-22 TW TW107129312A patent/TWI816690B/zh active
- 2018-08-22 WO PCT/CN2018/101699 patent/WO2019037737A1/en not_active Ceased
- 2018-08-22 SG SG11202001301RA patent/SG11202001301RA/en unknown
- 2018-08-22 PE PE2020000258A patent/PE20200887A1/es unknown
- 2018-08-22 MY MYPI2020000768A patent/MY200551A/en unknown
- 2018-08-22 JP JP2020511530A patent/JP7162964B2/ja active Active
- 2018-08-22 CA CA3072525A patent/CA3072525A1/en active Pending
- 2018-08-22 AU AU2018320010A patent/AU2018320010B2/en active Active
- 2018-08-22 EP EP18848142.8A patent/EP3672972A4/en active Pending
-
2020
- 2020-02-18 ZA ZA2020/01029A patent/ZA202001029B/en unknown
- 2020-02-21 CL CL2020000439A patent/CL2020000439A1/es unknown
- 2020-02-21 IL IL272835A patent/IL272835A/en unknown
- 2020-02-21 PH PH12020500366A patent/PH12020500366A1/en unknown
-
2022
- 2022-06-21 US US17/844,901 patent/US12084441B2/en active Active
-
2024
- 2024-08-07 US US18/796,480 patent/US20240391918A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| MX384752B (es) | ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR). | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| GEP20135992B (en) | Sulfonamide derivatives | |
| MX375925B (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MY209603A (en) | Hydroxypyridoxazepines as nrf2 activators | |
| MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| GEAP201814273A (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| MX2018006225A (es) | Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). | |
| MY194711A (en) | Novel annelated phenoxyacetamides | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones |